However, there has been no up-to-date systematic review examining whether SGLT2 inhibitors attenuate hyperfiltration in acute settings and in the early stages of diabetic nephropathy, whether SGLT2 inhibitors preserve GFR in the long term and for patients with more advanced nephropathy, or whether SGLT2 inhibitors reduce albuminuria. The gene discussed is SLC5A2; the disease is diabetic kidney disease.